Healthcare and Performance Materials more strongly affected by the Covid-19 pandemic than Life Science

06-Aug-2020

Merck registered the effects of the Covid-19 pandemic in all business sectors in the second quarter. Healthcare and Performance Materials were affected most strongly. In comparison with the year-earlier quarter, Group sales increased by 3.7% to € 4.1 billion. EBITDA pre, the Group’s most ...

more

Supports growing reference materials business

16-Jul-2020

Merck has announced plans to build a new, € 18 million laboratory facility in Buchs, Switzerland to support the company’s rapidly growing reference materials business. The company anticipates that about two dozen jobs will be created. "Researchers in testing labs around the world use Merck’s ...

more

Belén Garijo appointed Vice Chairman of the Executive Board and Deputy CEO

16-Jul-2020

The Board of Partners of E.MerckKG appointed Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO of Merck KGaA. She will maintain her current Executive Board responsibilities. “The appointment of Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO recognizes her ...

more

Prof. Sieber is developing approaches against multi-resistant pathogens

14-Jul-2020

Merck, a leading science and technology company, today announced the winner of the Future Insight Prize 2020, worth €1million. This year’s topic “Multi-Drug Resistance Breaker” relates to the health category. Prof.Stephan Sieber (44) is being awarded the Future Insight Prize 2020 for his ...

more

VAR2 Pharmaceuticals selected for its development of a drug-conjugated malaria protein

10-Jul-2020

Merck, a leading science and technology company, today announced that VAR2 Pharmaceuticals has been selected as the European winner of its 2020 Advance Biotech Grant Program. Copenhagen, Denmark-based biotechnology company VAR2 Pharmaceuticals was chosen for its development of a promising novel ...

more

Merck Advances Bioprocessing Capabilities with Raman Technology Sensor Acquisition

02-Jul-2020

Merck enhanced its advanced bioprocess portfolio through the acquisition of RESOLUTION Spectra Systems, a Meylan, France-based leader in bioprocess analytical monitoring. The company offers Raman spectroscopy analysis through its GMP-ready instrumentation and software. Financial details of the ...

more

First clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of Covid-19 infection

26-Jun-2020

Merck announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application (IND) for M5049 for the treatment of patients with Covid-19 pneumonia. Merck will initiate a Phase II randomized, controlled clinical study evaluating the safety and efficacy of M5049 ...

more

Company will focus on process development and improvements for manufacturing Baylor’s Covid-19 vaccine candidates

28-May-2020

Merck and Baylor College of Medicine, Houston, Texas, USA, announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, designed to accelerate transition to Phase 1 clinical trials. “Vaccine manufacturing is extremely complicated, so we are ...

more

New, € 100 million facility will more than double existing production capacity

22-Apr-2020

Merck announced a second Carlsbad, California, U.S.A.-based facility for its BioReliance® viral and gene therapy service offering. The new, €100 million commercial facility is expected to open next year. “Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the ...

more

Joint team reduced process development time to two months from a year

16-Apr-2020

Merck and The Jenner Institute announced that the Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid development of the large-scale manufacturing process is a ...

more